We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Abnormal Protein Potential Biomarker for ALS and FTD

By LabMedica International staff writers
Posted on 19 Feb 2013
Print article
Image: C9RANT Neuropathologgy: Immunohistochemistry of postmortem tissue reveals neuronal inclusions of C9RANT in the brains of patients with c9FTD/ALS (Photo courtesy of Neuron, Ash et al).
Image: C9RANT Neuropathologgy: Immunohistochemistry of postmortem tissue reveals neuronal inclusions of C9RANT in the brains of patients with c9FTD/ALS (Photo courtesy of Neuron, Ash et al).
Identification of abnormal protein may help diagnose and treat Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease and frontotemporal dementia (FTD).

Investigators have discovered an abnormal protein that first forms as a result of genetic abnormalities and later builds up in the brains of many patients with either disease. These investigators are beginning to recognize ALS and FTD as part of a spectrum disorder with overlapping symptoms.

By analyzing brain tissue from patients with ALS or FTD, Dr. Petrucelli, chair of neuroscience at Mayo Clinic in Florida (Jacksonville, FL, USA) and his team discovered that the abnormal protein, which they call C9RANT, is generated as a result of repeat expansions of nucleotides in the noncoding region of the C9ORF72 gene. These expansions are the most common cause of ALS and FTD. "Simply put, an error in the highly regulated cellular process through which proteins are generated causes the abnormal production of C9RANT," explained Dr. Petrucelli.

The scientists discovered the protein C9RANT after creating a novel antibody to specifically detect it. The ability to detect C9RANT in individuals' cerebrospinal fluid (CSF) may provide a valuable diagnostic and prognostic tool for identifying patients carrying the C9ORF72 repeat expansion and for then tracking the progression of the disease in these at-risk individuals.

Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, and frontotemporal dementia (FTD) are devastating neurodegenerative diseases with no effective treatment. "Although it remains to be shown whether C9RANT is causing the cell death or toxicity associated with disease symptoms, our discovery offers a potential target to prevent neuronal loss in patients carrying the C9ORF72 repeat expansion," said Dr. Petrucelli.

These studies were reported online in the February 12, 2013, Cell Press journal Neuron. The investigators described an abnormal protein that first forms as a result of genetic abnormalities and later builds up in the brains of many patients with ALS or FTD.

Related Links:

Mayo Clinic in Florida



New
Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Hemacytometer Cover Glasses
Propper Hemacytometer Cover Glasses
New
Thyroid Stimulating Hormone Assay
Neonatal TSH ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The inbiome molecular culture ID technology has received FDA breakthrough device designation (Photo courtesy of inbiome)

Revolutionary Molecular Culture ID Technology to Transform Bacterial Diagnostics

Bacterial infections pose a major threat to public health, contributing to one in five deaths worldwide. Current diagnostic methods often take several days to provide results, which can delay appropriate... Read more

Pathology

view channel
Image: Confocal- & laminar flow-based detection scheme of intact virus particles, one at a time (Photo courtesy of Paz Drori)

Breakthrough Virus Detection Technology Combines Confocal Fluorescence Microscopy with Microfluidic Laminar Flow

Current virus detection often relies on polymerase chain reaction (PCR), which, while highly accurate, can be slow, labor-intensive, and requires specialized lab equipment. Antigen-based tests provide... Read more

Industry

view channel
Image: The GeneXpert system’s fast PCR Xpert tests can fight AMR and superbugs with fast and accurate PCR in one hour (Photo courtesy of Cepheid)

Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance

Antimicrobial resistance (AMR) is responsible for over one million deaths globally each year and poses a growing challenge in treating major infectious diseases like tuberculosis, Escherichia coli (E.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.